Genmab — August 2023
-
NBI -0.65%.
-
In summary, our results assert the potential of epcoritamab as a novel treatment option for patients with CLL and support clinical investigations of epcoritamab in combination with BTKis or venetoclax and as salvage therapy in patients with progressing disease while receiving BTKi therapy.
-
-
Passer fint med at venetoclax er med i Epcore cll https://classic.clinicaltrials.gov/ct2/show/NCT04623541?term=Epcore+cll+1&draw=2&rank=1
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind